Concentration of tacrolimus and major metabolites in kidney transplant recipients as a function of diabetes mellitus and cytochrome P450 3A gene polymorphism

References

• Akhlaghi F, Dostalek M, Falck P, et al. (2012). The concentration of cyclosporine metabolites is significantly lower in kidney transplant recipients with diabetes mellitus. Ther Drug Monit 34:38–45
   PubMed Web of Science ®Google Scholar
• Akhlaghi F, Patel CG, Zuniga XP, et al. (2006). Pharmacokinetics of mycophenolic acid and metabolites in diabetic kidney transplant recipients. Ther Drug Monit 28:95–101
   PubMed Web of Science ®Google Scholar
• Ansermot N, Fathi M, Veuthey JL, et al. (2008). Quantification of cyclosporine and tacrolimus in whole blood. Comparison of liquid chromatography-electrospray mass spectrometry with the enzyme multiplied immunoassay technique. Clin Biochem 41:910–13
   Google Scholar
• Carvalho TM, Cavalli Rde C, Cunha SP, et al. (2011). Influence of gestational diabetes mellitus on the stereoselective kinetic disposition and metabolism of labetalol in hypertensive patients. Eur J Clin Pharmacol 67:55–61
   PubMed Web of Science ®Google Scholar
• Cheng PY, Morgan ET. (2001). Hepatic cytochrome P450 regulation in disease states. Curr Drug Metab 2:165–83
   PubMed Web of Science ®Google Scholar
• Christians U. (2005). Functional interactions between P-glycoprotein and CYP3A in drug metabolism. Expert Opin Drug Metab Toxicol 1:641–54
   PubMedGoogle Scholar
• Christians U, Jacobsen W, Serkova N, et al. (2000). Automated, fast and sensitive quantification of drugs in blood by liquid chromatography-mass spectrometry with on-line extraction: immunosuppressants. J Chromatogr B Biomed Sci Appl 748:41–53
   PubMed Web of Science ®Google Scholar
• Dai Y, Hebert MF, Isoherranen N, et al. (2006). Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos 34:836–47
   PubMed Web of Science ®Google Scholar
• Dostalek M, Akhlaghi F, Puzanovova M. (2012a). Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic properties of drugs. Clin Pharmacokinet 51:481–99
   PubMed Web of Science ®Google Scholar
• Dostalek M, Court MH, Hazarika S, et al. (2011b). Diabetes mellitus reduces activity of human UDP-glucuronosyltransferase 2B7 in liver and kidney leading to decreased formation of mycophenolic acid acyl-glucuronide metabolite. Drug Metab Dispos 39:448–55
   PubMed Web of Science ®Google Scholar
• Dostalek M, Court MH, Yan B, et al. (2011a). Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus. Br J Pharmacol 163:937–47
   PubMed Web of Science ®Google Scholar
• Dostalek M, Sam WJ, Paryani KR, et al. (2012b). Diabetes mellitus reduces the clearance of atorvastatin lactone: results of a population pharmacokinetic analysis in renal transplant recipients and in vitro studies using human liver microsomes. Clin Pharmacokinet 51:591–606
   PubMed Web of Science ®Google Scholar
• Firdaous I, Verbeeck RK, Hassoun A, et al. (1997). Excretion of tacrolimus glucuronides in human bile. Eur J Drug Metab Pharmacokinet 22:217–21
   PubMed Web of Science ®Google Scholar
• He P, Court MH, Greenblatt DJ, et al. (2005). Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin Pharmacol Ther 77:373–87
   PubMed Web of Science ®Google Scholar
• Hoffmeyer S, Burk O, von Richter O, et al. (2000). Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473–8
   PubMed Web of Science ®Google Scholar
• Hustert E, Haberl M, Burk O, et al. (2001). The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773–9
   PubMedGoogle Scholar
• Iwasaki K. (2007). Metabolism of tacrolimus (FK506) and recent topics in clinical pharmacokinetics. Drug Metab Pharmacokinet 22:328–35
   PubMed Web of Science ®Google Scholar
• Iwasaki K, Shiraga T, Nagase K, et al. (1993). Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone. Drug Metab Dispos 21:971–7
   PubMed Web of Science ®Google Scholar
• Johne A, Köpke K, Gerloff T, et al. (2002). Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 72:584–94
   PubMed Web of Science ®Google Scholar
• Kamdem LK, Streit F, Zanger UM, et al. (2005). Contribution of CYP3A5 to the in vitro hepatic clearance of tacrolimus. Clin Chem 51:1374–81
   PubMed Web of Science ®Google Scholar
• Karanam BV, Vincent SH, Newton DJ, et al. (1994). FK 506 metabolism in human liver microsomes: investigation of the involvement of cytochrome P450 isozymes other than CYP3A4. Drug Metab Dispos 22:811–14
   PubMed Web of Science ®Google Scholar
• Kerb R, Aynacioglu AS, Brockmoller J, et al. (2001). The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels. Pharmacogenom J 1:204–10
   PubMedGoogle Scholar
• Kuehl P, Zhang J, Lin Y, et al. (2001). Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383–91
   PubMed Web of Science ®Google Scholar
• Kuo HT, Sampaio MS, Vincenti F, et al. (2010). Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 56:1127–39
   PubMed Web of Science ®Google Scholar
• Lamba JK, Lin YS, Schuetz EG, et al. (2002). Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 54:1271–94
   PubMed Web of Science ®Google Scholar
• Lampen A, Christians U, Guengerich FP, et al. (1995). Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315–24
   PubMed Web of Science ®Google Scholar
• Laverdiere I, Caron P, Harvey M, et al. (2011). In vitro investigation of human UDP-glucuronosyltransferase isoforms responsible for tacrolimus glucuronidation: predominant contribution of UGT1A4. Drug Metab Dispos 39:1127–30
   PubMed Web of Science ®Google Scholar
• Mancinelli LM, Frassetto L, Floren LC, et al. (2001). The pharmacokinetics and metabolic disposition of tacrolimus: a comparison across ethnic groups. Clin Pharmacol Ther 69:24–31
   PubMed Web of Science ®Google Scholar
• Marques MP, Coelho EB, Dos Santos NA, et al. (2002). Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus. Eur J Clin Pharmacol 58:607–14
   PubMed Web of Science ®Google Scholar
• Mendonza AE, Zahir H, Gohh RY, et al. (2007). Tacrolimus in diabetic kidney transplant recipients: pharmacokinetics and application of a limited sampling strategy. Ther Drug Monit 29:391–8
   PubMed Web of Science ®Google Scholar
• Moises EC, Duarte Lde B, Cavalli Rde C, et al. (2008). Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. Eur J Clin Pharmacol 64:1189–96
   PubMed Web of Science ®Google Scholar
• Saeki T, Ueda K, Tanigawara Y, et al. (1993). Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem 268:6077–80
   PubMed Web of Science ®Google Scholar
• Sattler M, Guengerich FP, Yun CH, et al. (1992). Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753–61
   PubMed Web of Science ®Google Scholar
• Staatz CE, Goodman LK, Tett SE. (2010). Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I. Clin Pharmacokinet 49:141–75
   PubMed Web of Science ®Google Scholar
• Staatz CE, Tett SE. (2004). Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623–53
   PubMed Web of Science ®Google Scholar
• van Duijnhoven E, Christiaans M, Schäfer A, et al. (1998). Tacrolimus dosing requirements in diabetic and nondiabetic patients calculated from pretransplantation data. Transplant Proc 30:1266–7
   PubMed Web of Science ®Google Scholar
• Venkataramanan R, Swaminathan A, Prasad T, et al. (1995). Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404–30
   PubMed Web of Science ®Google Scholar
• Wild S, Roglic G, Green A, et al. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–53
   PubMed Web of Science ®Google Scholar
• Zini R, Riant P, Barre J, Tillement JP. (1990). Disease-induced variations in plasma protein levels. Implications for drug dosage regimens (Part I). Clin Pharmacokinet, 19:147–59
   PubMedGoogle Scholar